Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 9, 2024

Primary Completion Date

July 31, 2028

Study Completion Date

July 31, 2028

Conditions

SMARCB1-Deficient Malignancies

Interventions

DRUG

Ubamatamab

Given by IV

DRUG

Cemiplimab

Given by IV

Trial Locations (1)

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER